Jiangxia Wang

Jiangxia Wang

Auto-generated profile, based on publicly available information

Jiangxia Wang

Department of Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD; and

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
YLYuanyuan Liu
Yuanyuan Liu
JSJIKUI SHEN
JIKUI SHEN
SFSeth D. Fortmann
Seth D. Fortmann
JWJiangxia Wang
Jiangxia Wang
DVDietmar Vestweber
Dietmar Vestweber
PCPeter A. Campochiaro
Peter A. Campochiaro
Clinical trials in patients with macular edema due to diabetic retinopathy or retinal vein occlusion (RVO) have shown that suppression of VEGF not only improves macular edema, but also reopens closed retinal vessels, prevents progression of vessel closure, and improves retinopathy. In this study, we show the molecular basis for those clinical observations. Increased retinal levels of VEGF in mice cause plugging of retinal vessels with leukocytes, vessel closure, and hypoxia. Suppression of VEGF reduces leukocyte plugging, causing reperfusion of closed vessels. Activation of VEGFR1 contributes to leukocyte recruitment, because it is significantly reduced by an anti-VEGFR1–neutralizing antibody. High VEGF increases transcriptional activity of NF-κB and expression of NF-κB target genes, particularly Vcam1 . Injection of an anti-VCAM-1–neutralizing antibody reduces VEGF-induced leukocyte plugging. These data explain the broad range of benefits obtained by VEGF suppression in patients with ischemic retinopathies, provide an important insight into the pathogenesis of RVO and diabetic retinopathy, and suggest that sustained suppression of VEGF early in the course of these diseases may prevent vessel closure, worsening ischemia, and disease progression. This study also identifies VEGFR1 and VCAM-1 as molecular targets whose suppression could supplement VEGF neutralization for treatment of RVO and diabetic retinopathy.

28 January 2025 in Neurology
Verified
Journal Article
Closed access
ASAnja Soldan
Anja Soldan
CPCorinne Pettigrew
Corinne Pettigrew
JWJiangxia Wang
Jiangxia Wang
MAMarilyn S. Albert
Marilyn S. Albert
KBKaj Blennow
Kaj Blennow
AMAbhay Moghekar
Abhay Moghekar
Blood-based biomarkers of amyloid and tau have been shown to predict Alzheimer disease (AD) dementia. Much less is known about their ability to predict risk of mild cognitive impairment (MCI), an earlier disease stage. This study examined whether levels of blood biomarkers of amyloid (Aβ42/Aβ40 ratio), tau (p-tau181), neurodegeneration (NfL), and glial activation and neuroinflammation (glial fibrillary acidic protein [GFAP], YKL40, soluble triggering receptor expressed on myeloid cells 2 [sTREM2]) collected when participants were cognitively normal are associated with the time to onset of MCI. Cognitively unimpaired participants from the longitudinal observational BIOCARD study provided blood plasma at their baseline evaluation ("baseline 1"). A second "baseline" specimen (collected using slightly different procedures) was evaluated for participants who were still cognitively normal approximately 7 years later. The plasma assays were based on the NeuroToolKit (cobas Elecsys assays, Roche Diagnostics). Cox regression models tested the association of biomarker levels with time to MCI symptom onset, separately for both baselines. Participants included 271 individuals at "baseline 1" (mean age = 57.5 years, 60.5% female, including 82 who progressed to MCI/dementia) and 202 individuals at "baseline 2" (mean age = 64.5 years, 62.4% female, including 31 progressors). The mean clinical follow-up was 15.5 years for "baseline 1" and 9.9 years for "baseline 2." For both baselines, lower plasma Aβ42/Aβ40 ratio (both hazard ratios, HRs ≤ 0.69, 95% CIs ≤ 0.55-0.87, p ≤ 0.034), higher GFAP (HRs ≥ 1.83, CIs ≥ 1.28-2.60, p < 0.002), and a higher ratio of p-tau181/(Aβ42/Aβ40) (HRs ≥ 1.64, CIs ≥ 1.25-2.13, p ≤ 0.001) were each associated with an earlier time to MCI symptom onset. For baseline 2, higher p-tau181 (HR = 2.07, CI = 1.12-3.83, p = 0.021) and higher NfL (HR = 1.75, CI = 0.99-3.10, p = 0.05) were also associated with earlier MCI symptom onset for progression within 7 years. When combining biomarkers, neither GFAP nor NFL was associated with MCI symptom onset after accounting for AD biomarker levels (e.g., p-tau181/(Aβ42/Aβ40)), which remained significant. YKL40 and sTREM2 were not associated with MCI onset. Results indicate that during preclinical AD, more abnormal blood biomarker levels of amyloid (Aβ42/Aβ40), p-tau181, neurodegeneration (NfL), and neuroinflammation (GFAP) individually are associated with progression from normal cognition to MCI, but the AD-nonspecific neurodegeneration and inflammation markers were not associated with symptom onset after accounting for amyloid and p-tau levels.

5 January 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
BBBradley Beatson
Bradley Beatson
JWJiangxia Wang
Jiangxia Wang
MBMichael V. Boland
Michael V. Boland
PRPradeep Ramulu
Pradeep Ramulu
OSOliver Schein
Oliver Schein
DSDivya Srikumaran
Divya Srikumaran


1 April 2022 in Neurology Clinical Practice
Verified
Journal Article
Open access
PDF file
JDJacqueline A. Darrow
Jacqueline A. Darrow
ALAlexandria Lewis
Alexandria Lewis
SGSeema Gulyani
Seema Gulyani
KKKristina Khingelova
Kristina Khingelova
ARAruna Rao
Aruna Rao
AMAbhay Moghekar
Abhay Moghekar
Background and Objectives The assessment of biomarkers in selecting patients with idiopathic normal pressure hydrocephalus (iNPH) for shunt surgery has been limited to small cohort studies and those with limited follow-up. We assessed the potential for CSF biomarkers in predicting immediate response to CSF tap test (TT) and long-term response after shunt surgery. Methods CSF was obtained from patients with iNPH referred for CSF TT after baseline assessment of cognition and gait. CSF neurofilament light (NfL), β-amyloid 42 (Aβ1–42), β-amyloid 40 (Aβ1–40), total tau (tTau), and phosphorylated tau 181 (pTau181) and leucine-rich alpha-2-glycoprotein-1 (LRG1) were measured by ELISA. The ability of these measures to predict immediate improvement following CSF TT and long-term improvement following shunt surgery was compared by univariate and adjusted multivariate regression. Results Lower NfL, pTau181, tTau, and Aβ1–40 were individually predictive of long-term improvement in gait outcomes after shunt surgery. A multivariate model of these biomarkers and MRI Evans index, adjusted for age, improved prediction (area under the receiver operating curve 0.76, 95% confidence interval 0.66–0.86). tTau, pTau181, and Aβ1–40 levels were statistically different in those whose gait improved after CSF TT compared with those who did not. Using a multivariate model, combining these markers with Evans index and transependymal flow did not significantly improve prediction of an immediate response to CSF TT. Discussion A combination of CSF biomarkers can predict improvement following shunt surgery for iNPH. However, these measures only modestly discriminate responders from nonresponders following CSF TT. The findings further suggest that abnormal CSF biomarkers in nonresponders may represent comorbid neurodegenerative pathology or a predegenerative phase that presents with an iNPH phenotype.

18 March 2022 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Open access
CCCindy X. Cai
Cindy X. Cai
JKJanek M.A. Klawe
Janek M.A. Klawe
SASumayya Ahmad
Sumayya Ahmad
SZScott L. Zeger
Scott L. Zeger
JWJiangxia M.S. Wang
Jiangxia M.S. Wang
DSDivya Srikumaran
Divya Srikumaran
Purpose: To assess factors associated with gender disparities in cataract surgery volume and evaluate how these differences have changed over time. Setting: Cataract surgeons in the 2012 to 2018 Medicare database. Design: Retrospective study. Methods: The association of provider gender with the number of cataract surgeries per office visit billed was assessed with negative binomial regression models, controlling for calendar year, years in practice, hospital affiliation, geographic region, rurality, density of ophthalmologists, and the national percentile of Area Deprivation Index (ADI) score for the practice location. Results: There were 8480 cataract surgeons, most of whom were male (78%). Male surgeons worked in more deprived areas with a higher ADI (median: 40 vs 33, P < .001). Female surgeons performed fewer cataracts per year (140 [95% CI, 126-154] vs 276 [95% CI, 263-288], P < .001) and billed fewer office visits (1038 [95% CI, 1008-1068] vs 1505 [95% CI, 1484-1526], P < .001). In multivariate analysis, the number of cataract surgeries per office visit was greater for males compared with females in all years in the South (average incidence rate ratio 1.80), Midwest (1.50), and West (1.53), but not in the Northeast (1.16). The relative rate of cataract surgeries between male and female surgeons in each region did not change significantly over time from 2012 to 2018 (P > .05 in each region). Conclusions: Gender disparities in cataract volume among male and female surgeons have remained unchanged over time from 2012 to 2018. The higher cataract volume among male surgeons may be explained in part by provider practice location. Further studies are needed to better understand and address gender disparities.